vs
HOVNANIAN ENTERPRISES INC（HOV）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
HOVNANIAN ENTERPRISES INC的季度营收约是Revvity的1.1倍（$817.9M vs $772.1M），Revvity净利率更高（12.7% vs -0.1%，领先12.8%），Revvity同比增速更快（5.9% vs -16.5%），HOVNANIAN ENTERPRISES INC自由现金流更多（$164.0M vs $161.8M），过去两年HOVNANIAN ENTERPRISES INC的营收复合增速更高（17.3% vs 9.0%）
霍夫纳尼安企业是美国知名房地产企业，业务覆盖住宅开发全流程，包含设计、建造与销售，产品线丰富，不仅开发独立独栋住宅，也开发联排别墅、公寓以及养老住宅等高密度居住物业。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HOV vs RVTY — 直观对比
营收规模更大
HOV
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出22.4%
-16.5%
净利率更高
RVTY
高出12.8%
-0.1%
自由现金流更多
HOV
多$2.2M
$161.8M
两年增速更快
HOV
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $817.9M | $772.1M |
| 净利润 | $-667.0K | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -0.5% | 14.5% |
| 净利率 | -0.1% | 12.7% |
| 营收同比 | -16.5% | 5.9% |
| 净利润同比 | -100.7% | 3.9% |
| 每股收益（稀释后） | $-0.57 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOVRVTY
| Q4 25 | $817.9M | $772.1M | ||
| Q3 25 | $800.6M | $698.9M | ||
| Q2 25 | $686.5M | $720.3M | ||
| Q1 25 | $673.6M | $664.8M | ||
| Q4 24 | $979.6M | $729.4M | ||
| Q3 24 | $722.7M | $684.0M | ||
| Q2 24 | $708.4M | $691.7M | ||
| Q1 24 | $594.2M | $649.9M |
净利润HOVRVTY
| Q4 25 | $-667.0K | $98.4M | ||
| Q3 25 | $16.6M | $46.7M | ||
| Q2 25 | $19.7M | $53.9M | ||
| Q1 25 | $28.2M | $42.2M | ||
| Q4 24 | $94.3M | $94.6M | ||
| Q3 24 | $72.9M | $94.4M | ||
| Q2 24 | $50.8M | $55.4M | ||
| Q1 24 | $23.9M | $26.0M |
毛利率HOVRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率HOVRVTY
| Q4 25 | -0.5% | 14.5% | ||
| Q3 25 | 3.0% | 11.7% | ||
| Q2 25 | 3.9% | 12.6% | ||
| Q1 25 | 5.9% | 10.9% | ||
| Q4 24 | 12.0% | 16.3% | ||
| Q3 24 | 13.5% | 14.3% | ||
| Q2 24 | 9.8% | 12.4% | ||
| Q1 24 | 5.5% | 6.8% |
净利率HOVRVTY
| Q4 25 | -0.1% | 12.7% | ||
| Q3 25 | 2.1% | 6.7% | ||
| Q2 25 | 2.9% | 7.5% | ||
| Q1 25 | 4.2% | 6.4% | ||
| Q4 24 | 9.6% | 13.0% | ||
| Q3 24 | 10.1% | 13.8% | ||
| Q2 24 | 7.2% | 8.0% | ||
| Q1 24 | 4.0% | 4.0% |
每股收益（稀释后）HOVRVTY
| Q4 25 | $-0.57 | $0.86 | ||
| Q3 25 | $1.99 | $0.40 | ||
| Q2 25 | $2.43 | $0.46 | ||
| Q1 25 | $3.58 | $0.35 | ||
| Q4 24 | $12.47 | $0.77 | ||
| Q3 24 | $9.75 | $0.77 | ||
| Q2 24 | $6.66 | $0.45 | ||
| Q1 24 | $2.91 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $900.7M | — |
| 股东权益账面价值 | $830.9M | $7.3B |
| 总资产 | $2.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.08× | — |
8季度趋势，按日历期对齐
现金及短期投资HOVRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务HOVRVTY
| Q4 25 | $900.7M | — | ||
| Q3 25 | $861.9M | — | ||
| Q2 25 | $864.3M | — | ||
| Q1 25 | $893.7M | — | ||
| Q4 24 | $896.2M | — | ||
| Q3 24 | $898.7M | — | ||
| Q2 24 | $933.0M | — | ||
| Q1 24 | $934.6M | — |
股东权益HOVRVTY
| Q4 25 | $830.9M | $7.3B | ||
| Q3 25 | $835.4M | $7.4B | ||
| Q2 25 | $820.4M | $7.6B | ||
| Q1 25 | $811.4M | $7.6B | ||
| Q4 24 | $800.3M | $7.7B | ||
| Q3 24 | $703.4M | $7.9B | ||
| Q2 24 | $647.0M | $7.9B | ||
| Q1 24 | $607.1M | $7.8B |
总资产HOVRVTY
| Q4 25 | $2.6B | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.6B | $12.4B | ||
| Q1 25 | $2.5B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.5B | $12.8B | ||
| Q2 24 | $2.3B | $13.4B | ||
| Q1 24 | $2.3B | $13.4B |
负债/权益比HOVRVTY
| Q4 25 | 1.08× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.12× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.44× | — | ||
| Q1 24 | 1.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $169.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $164.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 20.0% | 21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $166.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HOVRVTY
| Q4 25 | $169.1M | $182.0M | ||
| Q3 25 | $52.8M | $138.5M | ||
| Q2 25 | $22.3M | $134.3M | ||
| Q1 25 | $-55.9M | $128.2M | ||
| Q4 24 | $115.8M | $174.2M | ||
| Q3 24 | $-92.3M | $147.9M | ||
| Q2 24 | $89.1M | $158.6M | ||
| Q1 24 | $-89.0M | $147.6M |
自由现金流HOVRVTY
| Q4 25 | $164.0M | $161.8M | ||
| Q3 25 | $45.8M | $120.0M | ||
| Q2 25 | $16.0M | $115.5M | ||
| Q1 25 | $-59.6M | $112.2M | ||
| Q4 24 | $111.4M | $149.8M | ||
| Q3 24 | $-95.8M | $125.6M | ||
| Q2 24 | $84.7M | $136.6M | ||
| Q1 24 | $-94.4M | $129.7M |
自由现金流率HOVRVTY
| Q4 25 | 20.0% | 21.0% | ||
| Q3 25 | 5.7% | 17.2% | ||
| Q2 25 | 2.3% | 16.0% | ||
| Q1 25 | -8.8% | 16.9% | ||
| Q4 24 | 11.4% | 20.5% | ||
| Q3 24 | -13.3% | 18.4% | ||
| Q2 24 | 12.0% | 19.7% | ||
| Q1 24 | -15.9% | 20.0% |
资本支出强度HOVRVTY
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 0.9% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 0.5% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% | ||
| Q1 24 | 0.9% | 2.7% |
现金转化率HOVRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 3.18× | 2.97× | ||
| Q2 25 | 1.13× | 2.49× | ||
| Q1 25 | -1.98× | 3.03× | ||
| Q4 24 | 1.23× | 1.84× | ||
| Q3 24 | -1.27× | 1.57× | ||
| Q2 24 | 1.75× | 2.87× | ||
| Q1 24 | -3.72× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOV
| Home Building | $789.8M | 97% |
| Financial Services | $28.1M | 3% |
| Management Fees | $7.1M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
